ClinicalTrials.gg
CompletedNCT03318809Updated Jun 23, 2022Results posted

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Participants With Severely Impaired Renal Function

A Phase 1 interventional study of AMG 986 in Heart Failure, sponsored by Amgen. Completed at 4 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-23.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 11 studies in Heart Failure by Amgen — 1 open to participants now, 1 under way, 1 of them phase 3. Heart Failure · Amgen.

Started
2017
with 1 other
Phase 1
2 of 11
none open now
Registered
8th of 11
by date

Among the 11 studies in Heart Failure by Amgen, this one is one of 2 that started in 2017, is one of 2 in phase 1, and was the 8th registered.

Heart Failure

6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

1 of the 11 studies in Heart Failure by Amgen is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Heart Failure by Amgen, or all of them as a file.
02

Study summary

A study to assess the safety, tolerability, and pharmacokinetics of AMG 986 given orally as a single dose to healthy participants and participants with severely impaired kidney function.

03

Conditions studied

  • Heart Failure

Keywords

  • Cardiovascular Diseases
  • Renal Impairment
  • Heart Diseases
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects, who are > or = 18 and \< or = 65 years of age at the time of screening
  • Subject has provided prior to initiation of any study-specific activities/procedures
  • Women must be of non- (ie, , history of hysterectomy, or history of bilateral oophorectomy)
  • Men must agree to practice an acceptable method of effective while on study through 11 weeks after receiving the dose of study drug.
  • Men must be willing to abstain from sperm donation while on study through 11 weeks after receiving the dose of study drug
  • > or = 18 and \< or = 38 kg/m\^2 at screening
  • Physical examination and 12-lead (ECGs) are clinically acceptable to the investigator
  • Non-hypertensive subjects or subjects with treated, stable hypertension as defined by blood pressure not exceeding 170/100 mm Hg as an average during screening and day -1; for subjects with renal impairment, no change in dosage and medication for > or = 4 weeks prior to screening, and expected to remain on this dose and medication for the entire duration of the study
  • Willing to maintain current general diet and physical activity regimen
  • Renal function in 1 of the following 2 categories at the time of screening: Group 1 - Severe Renal Impairment ( 15 to 29 mg/min/1.73 m\^2) and not anticipated to require hemodialysis or renal transplantation, and anticipated to have renal function appropriate to severe renal impairment for the duration of the study OR Group 2 - Normal renal function (eGFR > or = 90 mg/min/1.73 m\^2)

Exclusion criteria

Exclusion Criteria:

  • Subjects whose second modification of diet in renal disease () eGFR result on day -1 is not within 15% of the first eGFR result performed during the screening period. Healthy volunteers who have normal renal function, but show a difference greater than 15% in eGFR based on MDRD during the screening period, will be included in the trial at the discretion of the investigator and the sponsor after a 24-hour has been performed that meets eligibility criteria.
  • Subjects who are the recipient of a renal transplant and/or are on immunosupressants.
  • Subjects with a history of hospitalization for heart disease or angina within 4 months of screening.
  • Current or prior within 5 years of enrollment with the exception of non-melanoma skin cancers, cervical or breast ductal carcinoma in situ, and adenocarcinoma of the prostate Stage I or IIa (defined as T1, T2a or T2b, N0-, M0 with documented serum prostate-specific antigen (PSA) \< 20 ng/mL and Gleason score ≤ 7) per the American Joint Committee on Cancer (AJCC) primary tumor, regional lymph nodes, and distant system.
  • Positive for (HIV) antibodies, surface antigen (HBsAg) or virus antibodies (HepCAb) at screening
  • History or evidence of any other disorder, condition or disease with the exception of those outlined above that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
  • Subject previously has entered this study or has been previously exposed to AMG 986.
  • Heart rate ≥ 100 beats per minute after 5 minutes of rest or an untreated symptomatic bradyarrhythmia within 1 month prior to enrollment.
  • Known history of drug or alcohol abuse within last 12 months.
  • Currently receiving treatment in another device or drug study or less than 30 days or 5 half-lives (whichever is longer) since ending treatment on another investigational device or drug study(s) prior to receiving the dose of investigational product (AMG 986).
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Group 1: Severely Renal Impaired Participants

    Participants with severely impaired renal function (estimated glomerular filtration rate \[eGFR\] 15 to 29 mL/min/1.73 m\^2) receive a single oral dose of 200 mg AMG 986.

    Drug: AMG 986

  • Active comparator
    Group 2: Healthy Participants

    Participants with normal renal function (eGFR \>= 90 mL/min/1.73 m\^2 or above) receive a single oral dose of 200 mg AMG 986.

    Drug: AMG 986

Interventions

  • DrugAMG 986

    tablets for oral administration

06

What researchers measure

Primary outcomes

  1. AMG 986 Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Sample (AUClast)

    Time frame: Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose

  2. AMG 986 PK Parameter: Maximum Observed Plasma Concentration After Dosing (Cmax)

    Time frame: 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose

  3. AMG 986 PK Parameter: Terminal Phase Half-Life (t1/2,z)

    Time frame: Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose

  4. AMG 986 PK Parameter: Time of Maximum Plasma Concentration (Tmax)

    Time frame: Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose

  5. AMG 986 PK Parameter: Area Under the Plasma Concentration Time Curve From Time 0 to Infinity (AUCinf)

    Time frame: Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event is defined as any untoward medical occurrence in a clinical trial subject. A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: * fatal * life threatening (places the subject at immediate risk of death) * requires in patient hospitalization or prolongation of existing hospitalization * results in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event

    Time frame: From first dose of study drug up to Day 30

07

Results

Posted Jan 27, 2021

Participant flow

This study was conducted in 4 centers in the United States.

Participant flow — Overall Study
MilestoneGroup 1: Severely Renal Impaired ParticipantsGroup 2: Healthy Participants
Started66
Completed66
Not completed00

Outcome measures

PrimaryAMG 986 Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Sample (AUClast)
Time frame:
Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose
Reported as:
Geometric mean · hr*ng/mL
AMG 986 Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Sample (AUClast)
hr*ng/mLGroup 1: Severely Renal Impaired ParticipantsGroup 2: Healthy Participants
AMG 986 Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration Time Curve From Time 0 to the Time of the Last Quantifiable Sample (AUClast)80,000 ± 33.664,500 ± 70.0
Statistical analysis
  • Group 1: Severely Renal Impaired Participants vs Group 2: Healthy Participants · Ratio (group 1/group 2): 1.24 · 90% CI 0.73 to 2.10The ratio and confidence interval (CI) are based on natural log scale data converted back to the original scale.
PrimaryAMG 986 PK Parameter: Maximum Observed Plasma Concentration After Dosing (Cmax)
Time frame:
1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose
Reported as:
Geometric mean · ng/mL
AMG 986 PK Parameter: Maximum Observed Plasma Concentration After Dosing (Cmax)
ng/mLGroup 1: Severely Renal Impaired ParticipantsGroup 2: Healthy Participants
AMG 986 PK Parameter: Maximum Observed Plasma Concentration After Dosing (Cmax)10,600 ± 45.37520 ± 50.5
Statistical analysis
  • Group 1: Severely Renal Impaired Participants vs Group 2: Healthy Participants · Ratio (group 1/group 2): 1.41 · 90% CI 0.88 to 2.27The ratio and CI are based on natural log scale data converted back to the original scale.
PrimaryAMG 986 PK Parameter: Terminal Phase Half-Life (t1/2,z)
Time frame:
Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose
Reported as:
Geometric mean · hours
AMG 986 PK Parameter: Terminal Phase Half-Life (t1/2,z)
hoursGroup 1: Severely Renal Impaired ParticipantsGroup 2: Healthy Participants
AMG 986 PK Parameter: Terminal Phase Half-Life (t1/2,z)18.4 ± 21.121.1 ± 44.6
PrimaryAMG 986 PK Parameter: Time of Maximum Plasma Concentration (Tmax)
Time frame:
Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose
Reported as:
Median · hours
AMG 986 PK Parameter: Time of Maximum Plasma Concentration (Tmax)
hoursGroup 1: Severely Renal Impaired ParticipantsGroup 2: Healthy Participants
AMG 986 PK Parameter: Time of Maximum Plasma Concentration (Tmax)1.1 (1.0 to 2.1)1.5 (1.1 to 4.1)
PrimaryAMG 986 PK Parameter: Area Under the Plasma Concentration Time Curve From Time 0 to Infinity (AUCinf)
Time frame:
Predose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
AMG 986 PK Parameter: Area Under the Plasma Concentration Time Curve From Time 0 to Infinity (AUCinf)
ng*hr/mLGroup 1: Severely Renal Impaired ParticipantsGroup 2: Healthy Participants
AMG 986 PK Parameter: Area Under the Plasma Concentration Time Curve From Time 0 to Infinity (AUCinf)80,800 ± 33.665,800 ± 68.8
Statistical analysis
  • Group 1: Severely Renal Impaired Participants vs Group 2: Healthy Participants · Ratio (group 1/group 2): 1.24 · 90% CI 0.73 to 2.10The ratio and CI are based on natural log scale data converted back to the original scale.
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event is defined as any untoward medical occurrence in a clinical trial subject. A serious adverse event is defined as an adverse event that meets at least 1 of the following serious criteria: * fatal * life threatening (places the subject at immediate risk of death) * requires in patient hospitalization or prolongation of existing hospitalization * results in persistent or significant disability/incapacity * congenital anomaly/birth defect * other medically important serious event

Time frame:
From first dose of study drug up to Day 30
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
participantsGroup 1: Severely Renal Impaired ParticipantsGroup 2: Healthy Participants
TEAEs21
Serious TEAEs00

Adverse events

Collected over From first dose of study drug up to Day 30. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Severely Renal Impaired Participants0/6 (0%)0/6 (0%)2/6 (33.3%)
Group 2: Healthy Participants0/6 (0%)0/6 (0%)1/6 (16.7%)
Most frequent other events
Most frequent other events
EventGroup 1: Severely Renal Impaired ParticipantsGroup 2: Healthy Participants
NauseaGastrointestinal disorders0/61/6
DizzinessNervous system disorders0/61/6
HeadacheNervous system disorders1/60/6
DyspnoeaRespiratory, thoracic and mediastinal disorders1/60/6

Baseline characteristics

The safety analysis set included all study participants who received at least 1 dose of AMG 986.

Age, Continuous
Age, Continuous(years)Group 1: Severely Renal Impaired ParticipantsGroup 2: Healthy ParticipantsTotal
Mean56.7 ± 8.157.8 ± 3.357.3 ± 5.9
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: Severely Renal Impaired ParticipantsGroup 2: Healthy ParticipantsTotal
Female336
Male336
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: Severely Renal Impaired ParticipantsGroup 2: Healthy ParticipantsTotal
Hispanic or Latino011
Not Hispanic or Latino6511
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group 1: Severely Renal Impaired ParticipantsGroup 2: Healthy ParticipantsTotal
Asian112
Black (or African American)336
White224
08

Study locations

4 sites
  • Research Site
    Tustin, California 92780, United States
  • Research Site
    Orlando, Florida 32809, United States
  • Research Site
    Minneapolis, Minnesota 55404, United States
  • Research Site
    San Antonio, Texas 78215, United States
09

References and documents

Publications

  • Trivedi A, Mather O, Vega S, Simiens MA, Hellawell J, Lee E. Effect of Severe Renal Impairment on the Safety, Tolerability, and Pharmacokinetics of AMG 986. Drugs R D. 2022 Mar;22(1):89-94. doi: 10.1007/s40268-021-00380-1. Epub 2022 Jan 29. PubMed 35092583 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Mar 2018, 3 months.

Results were first posted in Jan 2021, 2 years 10 months after primary completion.

Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 3 months is below that.

Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2017
First posted
Oct 24, 2017
StartActual
Dec 12, 2017
Primary completionActual
Mar 12, 2018
CompletionActual
Apr 5, 2018
Results first posted
Jan 27, 2021
Last update
Jun 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03318809
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 24, 2017
Start date
Dec 12, 2017
Primary completion
Mar 12, 2018
Completion
Apr 5, 2018
Results posted
Jan 27, 2021
Last update
Jun 23, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion